Merck and Tencent announce collaboration on intelligent digital healthcare services in China
- Details
- Category: Merck Group
Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public disease awareness and providing more accessible healthcare services via digital platforms in China, by leveraging the company's scientific leadership and expertise combined with Tencent's leading technology in the fields of internet and artificial intelligence.
A healthy 2019: Four paws for more relaxation and exercise
- Details
- Category: Boehringer Ingelheim
Pets spend their whole lives at their owners' sides, keeping them active and comforting them in times of illness or loneliness. A study conducted by research organization IPSOS on behalf of Boehringer Ingelheim recently confirmed what many pet owners have long suspected: Dogs, cats and other pets have a positive impact on health and well-being.
FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin)
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.
Amgen and UCB receive positive vote from FDA Advisory Committee in favor of approval for EVENITY™ (romosozumab)
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies.
Merck welcomes ten new startups to its Innovation Center
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the ten startups that will be joining the seventh intake of its Accelerator program at the Merck Innovation Center in Darmstadt. The teams come from nine different countries, making 2019 the most international intake in the Merck Accelerator's history. They were chosen from a total of 565 applications, coming from startups based in 68 countries across the world.
Abbott to acquire Cephea Valve Technologies, Inc.
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced today that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an option to purchase Cephea in 2015.
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ("low-dose") for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).
More Pharma News ...
- US FDA accepts regulatory submissions for review of tafamidis to treat transthyretin amyloid cardiomyopathy
- EVENITY™ (romosozumab) receives approval in Japan for the treatment of osteoporosis in patients at high risk of fracture
- Boehringer Ingelheim initiates a collaborative partnership with Science 37 to accelerate patient centricity in the development of novel therapies
- Sandoz and Pear Therapeutics announce US launch of reSET-OTM to help treat Opioid Use Disorder
- AstraZeneca announces organisational changes
- Pfizer initiates phase 2b/3 clinical trial for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with moderate to severe alopecia areata
- Bristol-Myers Squibb to acquire Celgene to create a premier innovative biopharma company